afar american federation for aging research

Scientific Symposium

Discussing new therapies in aging research.
Highlighting opportunities for investment.

November 6, 2018

Lotte New York Palace
455 Madison Avenue

About our Moderator

Pol Vandenbroucke, M.D., M.Sc., M.B.A., F.F.P.M.

Senior Vice President and Chief Development Officer, Pfizer Essential Health

Dr. Vandenbroucke's career has been dedicated to Clinical Development, Medical Affairs, and Marketing in the U.S., Europe, Asia, and Latin America. Before his current position, he was responsible for Medical Strategy for Pfizer Inc. and for Medical Affairs of Pfizer's Essential Health portfolio in North America. He previously also led the Clinical Development of all Pfizer compounds in Asia, Central/Eastern Europe, Latin America, and Africa-Middle East and of Pfizer's Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness. Dr. Vandenbroucke serves on the boards of AFAR and BIO Ventures for Global Health. He is a member of the advisory boards of the Steve Biko Centre for Bioethics, University of the Witwatersrand-Johannesburg, the Canadian Institutes of Health Research, and the Keck Graduate Institute, Claremont, CA. He also is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom. A frequent speaker on health, aging, diversity, and policy issues, he is also a Visiting Senior Lecturer at King's College and the Module Co-ordinator for Medical Affairs in the Medicines Development Certificate Program at IFAPP Academy and King's College London.

About our Presenters



Nir Barzilai, M.D.

Director of the Institute for Aging Research, Principal Investigator of the Nathan Shock Center of Excellence in the Biology of Aging, and Principal Investigator of the Paul F. Glenn Center for the Biology of Human Aging, at Albert Einstein College of Medicine; AFAR Deputy Scientific Director; Founder and Board member of CohBar Inc.; Chief Medical Advisor for Life Biosciences

Dr. Barzilai is a chaired Professor of Medicine and Genetics, as well as Director of the biggest center in the world to study the biology of aging, at Albert Einstein College of Medicine. He is the recipient of the National Institutes of Health Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the 2010 AFAR Irving S. Wright Award and the 2018 IPSEN Longevity award. He is leading the TAME (Targeting Aging with Metformin) Trial, a multi-central study that aims to provide proof-of-concept that multi-morbidities of aging can be delayed in humans and to change the FDA indications to allow for next generation interventions. He has been featured in major papers, TV programs, and documentaries, including *The Economist, National Geographic Channel, PBS, the Wall Street Journal,* and *WIRED*. Dr. Barzilai has been invited to present and consult on promising interventions for targeting aging at The Singapore Prime Minister Office, Pepsico, the Milken Institute, as well as several international banks. Dr. Barzilai received AFAR's Paul B. Beeson Emerging Leaders Career Development Award in Aging in 1997, as well as an AFAR Research Grant in 1994.

Veronica Galvan, Ph.D.

Associate Professor in the Department of Cellular and Integrative Physiology at the Barshop Institute for Longevity and Aging Research, and the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, at the University of Texas Health San Antonio

Dr. Galvan's research focuses on the identification of molecular and biochemical alterations that cause Alzheimer's disease and other dementias. She has generated novel experimental models of Alzheimer's and used them to identify novel mechanisms of neurodegeneration in this disease. Dr. Galvan pioneered the study of mechanisms that link brain aging to the pathogenesis of Alzheimer's and other dementias. Her laboratory provided the first demonstration of a role of the target of rapamycin (TOR), a central regulator of mammalian aging, in the initiation of Alzheimer's-like disease and vascular dementia in surrogate models. Dr. Galvan's group also reported the accumulation of pathological forms of tau protein in brain microvasculature in Alzheimer's and other tauopathies. Major research goals of the Galvan Laboratory are to define how TOR links brain aging to the initiation and progression of Alzheimer's disease and other dementias and understand how the accumulation of misfolded forms of tau in brain vasculature drive cerebrovascular and cognitive dysfunction in neurodegenerative disease. She has joint appointments in the Neurosciences, Biology of Aging, and Physiology and Pharmacology graduate programs at UTHSA. Dr. Galvan also serves as Research Health Scientist at the Department of Veterans Affairs.

We wish to thank Pfizer Inc. and Regeneron for their generous support of today's Symposium

Thomas Rando, M.D., Ph.D.

Professor of Neurology and Neurological Sciences, and Founding Director of the Glenn Center for the Biology of Aging at Stanford University; Deputy Director of the Stanford Center on Longevity

Dr. Rando's research focuses on stem cell biology, with particular interest in stem cell aging. He has pioneered the field of systemic factors as regulators of cellular aging based upon seminal studies done in his laboratory using the technique of heterochronic parabiosis. These studies initiated an entire segment of research in aging that has led to the identification of factors in the blood that influence cell and tissue aging. Work in Dr. Rando's laboratory has also provided the foundation for studies of the epigenetics of stem cell function and stem cell aging, leading to the concept of "epigenetic rejuvenation" by which interventions (e.g., dietary, pharmacologic, parabiotic) may slow or even reverse the processes of aging. Dr. Rando received both the Director's Pioneer Award and a Transformative Research Award from the National Institutes of Health. Dr. Rando is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science. Additionally, Dr. Rando directs the Center for Tissue Regeneration, Repair, and Restoration, a program in regenerative medicine combining expertise in stem cell biology and bioengineering, at the VA Palo Alto Health Care System, where he is also Chief of Neurology. Dr. Rando received AFAR's Paul B. Beeson Emerging Leaders Career Development Award in Aging in 1999 and Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award in 2008, and serves on AFAR's board of directors.



David Sinclair, Ph.D.

Professor of Genetics and co-Director of the Paul F. Glenn Center for the Biological Mechanisms of Aging at Harvard Medical School; Professor and Head of the Aging Labs at the University of New South Wales, Sydney

Dr. Sinclair is best known for his work on genes and small molecules that delay aging, including the Sirtuin genes, resveratrol, and NAD precursors. He is regarded as one of the world's leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the processes of aging. He has published over 160 scientific papers, is a co-inventor on 50 patents, and has co-founded biotechnology companies in the areas of aging, vaccines, diabetes, fertility, cancer, and biodefense. He is co-chief editor of the scientific journal *Aging* and works with national defense agencies, as well as NASA. He has received 35 honors including the CSL prize, an Advance Global Award, an ASMR Medal, the National Institutes of Health's Director's Pioneer award, a Member of the Order of Australia (Australia's knighthood), and *TIME* magazine's list of the "100 most influential people in the world." Dr. Sinclair's work has been featured in five books, two documentary movies, on *CBS 60 Minutes*, in Morgan Freeman's "Through the Wormhole," *National Geographic Channel, PBS, TEDMed,* and more. Dr. Sinclair serves on the AFAR board of directors; he received an AFAR Research Grant in 2000.

american federation
for aging research

The American Federation for Aging Research (AFAR) is a national, non-profit organization whose mission is to support and advance healthy aging through biomedical research.

Since 1981, AFAR has advanced basic research and breakthroughs in the science of healthy aging by supporting more than 4,100 talented MDs, PhDs, and students across the country.

What AFAR-supported scientists are learning today about the processes of aging will help us all live healthier, longer tomorrow—less susceptible to disease and disability.

Learn more at www.afar.org or follow AFARorg on Twitter and Facebook.